Mebendazole Chemotherapy Combo Enhances Macrophage Modulation in Cancer

Mebendazole, a well-known antiparasitic drug from the benzimidazole class, has been increasingly investigated for its potential anticancer properties. Previous research has demonstrated that mebendazole can directly kill cancer cells through various mechanisms, but its indirect effects through immune modulation have been less well characterized.

A 2026 study published in Oncology Reports by researchers from Uppsala University and Akademiska Hospital in Sweden provides new evidence that mebendazole's anticancer effects may extend beyond direct cytotoxicity to include modulation of the tumor immune microenvironment. The study used both patient-derived tumor cells and a mouse colon cancer model to investigate these effects.

Readers interested in the broader context of mebendazole and other antiparasitic drugs in cancer may find our Marik protocol article relevant. For practical dosing guidance, see our protocol dosing workspace.

Table of Contents

• What Did the Study Examine?
• What Happened in Patient-Derived Tumor Cells?
• What Happened in the Mouse Model?
• What Does This Mean?
• Limitations and Evidence Level
• Frequently Asked Questions

What Did the Study Examine?

The researchers, led by Mansoori and colleagues, investigated the anticancer effects of mebendazole in several experimental systems:

• Patient-derived tumor cells: Primary cultures from acute myeloid leukemia (AML), ovarian, colorectal, and renal cancer patients.
• CT26 mouse colon cancer cells: Both in vitro and in vivo experiments.
• Chemotherapy combinations: Mebendazole was tested alone and in combination with irinotecan, cisplatin, or gemcitabine.

The study used the fluorometric microculture cytotoxicity assay (FMCA) to measure cell viability, and flow cytometry to analyze immune cell infiltration in resected mouse tumors.

What Happened in Patient-Derived Tumor Cells?

Mebendazole showed modest single-agent cytotoxicity across the patient tumor cell samples, with acute myeloid leukemia cells being the most sensitive. However, when combined with cytotoxic drugs, mebendazole displayed enhanced effects, particularly in combination with irinotecan.

The finding that mebendazole enhances chemotherapy effects in patient tumor cells is significant because it suggests potential synergy between standard cancer treatments and this repurposed drug. This is particularly relevant for solid tumors, where mebendazole was tested in combination with irinotecan, cisplatin, and gemcitabine.

What Happened in the Mouse Model?

In the BALB/c CT26 colon cancer mouse model, both mebendazole and irinotecan individually inhibited tumor growth. However, the combination of mebendazole and irinotecan did not significantly outperform mebendazole alone in this specific model, suggesting that the synergy observed in patient cells may be tumor-type dependent.

The most significant finding came from flow cytometry analysis of resected mouse tumors. The researchers found that mebendazole promoted macrophage polarization from the M2 phenotype (which promotes tumor growth and immunosuppression) to the M1 phenotype (which is pro-inflammatory and anti-tumor). This immune modulation may contribute to mebendazole's overall anticancer effect.

What Does This Mean?

The finding that mebendazole can modulate macrophage polarization adds a new dimension to our understanding of its anticancer mechanisms. Tumor-associated macrophages (TAMs) are one of the most abundant immune cell types in the tumor microenvironment, and their M2 phenotype is associated with tumor progression, angiogenesis, and resistance to therapy. Reprogramming these macrophages toward the M1 phenotype could enhance the effectiveness of both immunotherapy and conventional chemotherapy.

This study was conducted by researchers affiliated with Repos Pharma AB, a Swedish company dedicated to drug repositioning research. The authors declared that the company was not involved in the study design, execution, data analysis, or writing of the manuscript.

Limitations and Evidence Level

This study is preclinical and carries several limitations:

• Ex vivo and animal models: The patient cells were cultured outside the body, and the mouse model may not reflect human tumor biology.
• Modest single-agent effects: Mebendazole alone showed only modest cytotoxicity, suggesting it may be most useful as part of combination therapy.
• Combination inconsistency: Synergy was seen in patient cells but not consistently in the mouse model, suggesting tumor-type dependence.
• Early stage: No clinical trial data is available for this specific combination approach.

Frequently Asked Questions

Shop Sanare Lab

Lab-tested benzimidazole compounds for researchers exploring repurposed antiparasitic oncology.

Disclaimer: Links are informational and do not constitute medical advice. Always consult a healthcare provider before using any supplement or medication.

References

1. Mansoori S, Blom K, Andersson C, Fryknas M, Larsson R, Nygren P. Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model. Oncology Reports. 2026;55(1):9. doi:10.3892/or.2025.9014

Medical Disclaimer

The information provided in this article is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any decisions about your health or treatment. This article describes preclinical research in laboratory cells and animal models. No human clinical trial data is available for this specific approach. Self-administration of any drug without medical supervision can be dangerous.